iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://doi.org/10.1007/s13181-015-0488-6
A Review of the Toxicologic Implications of Obesity | Journal of Medical Toxicology Skip to main content

Advertisement

Springer Nature Link
Log in

A Review of the Toxicologic Implications of Obesity

  • Review Article
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

The increasing prevalence of obesity in developed nations has far-reaching implications for medical toxicology. The management of obese patients is complicated by comorbid illnesses, changes in cardiovascular and respiratory physiology, alterations in pharmacokinetics, and a lack of studies to identify appropriate dosing for current therapeutics and antidotes. In this review article, we examine obesity-associated physiologic and pharmacokinetic changes that may increase the vulnerability of obese patients to overdose. Further research is needed to characterize the relationship between drug toxicity and obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Freedman DS, CDC. Obesity—United States, 1988–2008. MMWR Surveill Summ. 2011;60(Suppl):73–7.

    PubMed  Google Scholar 

  2. May AL, Freedman D, Sherry B, Blanck HM, CDC. Obesity—United States, 1999–2010. MMWR Surveill Summ. 2013;62 Suppl 3:120–8.

    PubMed  Google Scholar 

  3. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. doi:10.1016/j.jacc.2013.11.004.

    Article  PubMed  Google Scholar 

  4. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.

  5. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998;68(4):899–917.

    Google Scholar 

  6. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. doi:10.1001/jama.2014.732.

    Article  CAS  PubMed  Google Scholar 

  7. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief. 2012;(82):1–8.

  8. NCHS. Health, United States, 2012: with special feature on emergency care. Hyattsville, Maryland; 2013.

  9. Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563–70. doi:10.1016/j.amepre.2011.10.026.

    Article  PubMed  Google Scholar 

  10. Hill JO. Environmental contributions to the obesity epidemic. Science. 1998;280(5368):1371–4.

    Article  CAS  PubMed  Google Scholar 

  11. Cutler D, Glaeser E, Shapiro J. Why have Americans become more obese? J Econ Perspect. 2003;17(3):93–118.

    Article  Google Scholar 

  12. Du H, Feskens E. Dietary determinants of obesity. Acta Cardiol. 2010;65(4):377–86.

    PubMed  Google Scholar 

  13. Mitchell JA, Byun W. Sedentary behavior and health outcomes in children and adolescents. Am J Lifestyle Med. 2013. doi:10.1177/1559827613498700.

    Google Scholar 

  14. McVinnie DS. Obesity and pain. Br J Pain. 2013;7(4):163–70.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann Intern Med. 1985;103(1):147–51.

  16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423.

    Article  PubMed  Google Scholar 

  17. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. doi:10.1001/jama.2012.113905.

    Article  CAS  PubMed  Google Scholar 

  18. Mack KA, CDC. Drug-induced deaths—United States, 1999–2010. MMWR Surveill Summ. 2013;62 Suppl 3:161–3.

    PubMed  Google Scholar 

  19. Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006;16(6):773–6. doi:10.1381/096089206777346673.

    Article  PubMed  Google Scholar 

  20. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321(4):225–36.

    Article  CAS  PubMed  Google Scholar 

  21. Ferraro S, Perrone-Filardi P, Desiderio A, Betocchi S, D’Alto M, Liguori L, et al. Left ventricular systolic and diastolic function in severe obesity: a radionuclide study. Cardiology. 1996;87(4):347–53.

    Article  CAS  PubMed  Google Scholar 

  22. Lee JF, Harrison ML, Christmas KM, Kim K, Hurr C, Brothers RM. Elevated resting heart rate and reduced orthostatic tolerance in obese humans. Clin Auton Res. 2013. doi:10.1007/s10286-013-0222-x.

    Google Scholar 

  23. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978;40(15):1607–10.

    Article  Google Scholar 

  24. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898–918. doi:10.1161/CIRCULATIONAHA.106.171016.

    Article  PubMed  Google Scholar 

  25. Strandgaard S, Andersen GS, Ahlgreen P, Nielsen PE. Visual disturbances and occipital brain infarct following acute, transient hypotension in hypertensive patients. Acta Med Scand. 1984;216(4):417–22.

    Article  CAS  PubMed  Google Scholar 

  26. McLaren GD, Danta G. Cerebral infarction due to presumed haemodynamic factors in ambulant hypertensive patients. Clin Exp Neurol. 1987;23:55–66.

    CAS  PubMed  Google Scholar 

  27. Honiden S. Caring for the critically ill, obese patient. PCCSU; 2011.

  28. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev. 2007;11(1):35–46. doi:10.1016/j.smrv.2006.03.006.

    Article  PubMed  Google Scholar 

  29. Mogri M, Desai H, Webster L, Grant BJ, Mador MJ. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath. 2009;13(1):49–57. doi:10.1007/s11325-008-0208-4.

    Article  PubMed  Google Scholar 

  30. Harris AT, Morell D, Bajaj Y, Martin-Hirsch DP. A discussion of airway and respiratory complications along with general considerations in obese patients. Int J Clin Pract. 2010;64(6):802–6. doi:10.1111/j.1742-1241.2010.02350.x.

    Article  CAS  PubMed  Google Scholar 

  31. Ramachandran SK, Haider N, Saran KA, Mathis M, Kim J, Morris M, et al. Life-threatening critical respiratory events: a retrospective study of postoperative patients found unresponsive during analgesic therapy. J Clin Anesth. 2011;23(3):207–13. doi:10.1016/j.jclinane.2010.09.003.

    Article  PubMed  Google Scholar 

  32. Mushref MA, Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility. Ann Transl Med. 2013;1(2):14. doi:10.3978/j.issn.2305-5839.2012.11.01.

    PubMed Central  PubMed  Google Scholar 

  33. Cardoso-Junior A, Coelho LG, Savassi-Rocha PR, Vignolo MC, Abrantes MM, de Almeida AM, et al. Gastric emptying of solids and semi-solids in morbidly obese and non-obese subjects: an assessment using the 13C-octanoic acid and 13C-acetic acid breath tests. Obes Surg. 2007;17(2):236–41.

    Article  PubMed  Google Scholar 

  34. Acosta A, Camilleri M, Shin A, Vazquez-Roque MI, Iturrino J, Burton D, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015;148(3):537–46 e4. doi:10.1053/j.gastro.2014.11.020.

  35. Wright RA, Krinsky S, Fleeman C, Trujillo J, Teague E. Gastric emptying and obesity. Gastroenterology. 1983;84(4):747–51.

    CAS  PubMed  Google Scholar 

  36. Jackson SJ, Leahy FE, McGowan AA, Bluck LJ, Coward WA, Jebb SA. Delayed gastric emptying in the obese: an assessment using the non-invasive (13)C-octanoic acid breath test. Diabetes Obes Metab. 2004;6(4):264–70. doi:10.1111/j.1462-8902.2004.0344.x.

    Article  CAS  PubMed  Google Scholar 

  37. Horowitz M, Collins PJ, Cook DJ, Harding PE, Shearman DJ. Abnormalities of gastric emptying in obese patients. Int J Obes. 1983;7(5):415–21.

    CAS  PubMed  Google Scholar 

  38. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27–42.

    Article  CAS  PubMed  Google Scholar 

  39. Cikim AS, Topal E, Harputluoglu M, Keskin L, Zengin Z, Cikim K, et al. Epicardial adipose tissue, hepatic steatosis and obesity. J Endocrinol Investig. 2007;30(6):459–64.

    Article  CAS  Google Scholar 

  40. Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab. 2011;12(1):24–34.

    Article  CAS  PubMed  Google Scholar 

  41. Pan A, Sun Q, Czernichow S, Kivimaki M, Okereke OI, Lucas M, et al. Bidirectional association between depression and obesity in middle-aged and older women. Int J Obes (Lond). 2012;36(4):595–602. doi:10.1038/ijo.2011.111.

    Article  CAS  Google Scholar 

  42. Dixon JB, Dixon ME, O’Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003;163(17):2058–65. doi:10.1001/archinte.163.17.2058.

    Article  PubMed  Google Scholar 

  43. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634–51, quiz 730.

  44. Alcaro A, Panksepp J. The SEEKING mind: primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression. Neurosci Biobehav Rev. 2011;35(9):1805–20. doi:10.1016/j.neubiorev.2011.03.002.

    Article  PubMed  Google Scholar 

  45. Wang GJ, Volkow ND, Thanos PK, Fowler JS. Imaging of brain dopamine pathways: implications for understanding obesity. J Addict Med. 2009;3(1):8–18. doi:10.1097/ADM.0b013e31819a86f7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Baik JH. Dopamine signaling in reward-related behaviors. Front Neural Circ. 2013;7:152. doi:10.3389/fncir.2013.00152.

    Google Scholar 

  47. Bluml V, Kapusta N, Vyssoki B, Kogoj D, Walter H, Lesch OM. Relationship between substance use and body mass index in young males. Am J Addict. 2012;21(1):72–7. doi:10.1111/j.1521-0391.2011.00192.x.

    Article  PubMed  Google Scholar 

  48. Gearhardt AN, Harrison EL, McKee SA. Does co-morbid depression alter the inverse relationship between obesity and substance use disorders? Drug Alcohol Depend. 2012;124(1–2):185–8. doi:10.1016/j.drugalcdep.2012.01.002.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Hitt HC, McMillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of obesity and pain in a general population: results from the Southern Pain Prevalence Study. J Pain. 2007;8(5):430–6. doi:10.1016/j.jpain.2006.12.003.

    Article  PubMed  Google Scholar 

  50. Counterweight Project Team. The impact of obesity on drug prescribing in primary care. Br J Gen Pract. 2005;55(519):743–9.

    PubMed Central  Google Scholar 

  51. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92. doi:10.7326/0003-4819-152-2-201001190-00006.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Phys. 2012;15(3 Suppl):ES9–38.

    Google Scholar 

  53. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8. doi:10.1038/sj.clpt.6100381.

    Article  CAS  PubMed  Google Scholar 

  54. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87. doi:10.2165/11318100-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  55. Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  56. Du BD, Du BE. Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;XVII(6_2):863–71. doi:10.1001/archinte.1916.00080130010002.

    Article  Google Scholar 

  57. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi:10.1056/NEJM198710223171717.

    CAS  PubMed  Google Scholar 

  58. Lopes-Serrao MD, Ussery SM, Hall RG, Shah SR. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract. 2011;7(1):13–7. doi:10.1200/JOP.2010.000045.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–61. doi:10.1200/JCO.2011.39.9436.

    Article  PubMed  Google Scholar 

  60. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31. doi:10.2165/00003088-200039030-00004.

    Article  CAS  PubMed  Google Scholar 

  61. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–33. doi:10.1111/j.1365-2125.2004.02157.x.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994;26(4):292–307. doi:10.2165/00003088-199426040-00005.

    Article  CAS  PubMed  Google Scholar 

  63. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65. doi:10.2165/00003088-200544100-00004.

    Article  PubMed  Google Scholar 

  64. De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain. 2004;4(5):152–5. doi:10.1093/bjaceaccp/mkh042.

    Article  Google Scholar 

  65. Casati A, Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth. 2005;17(2):134–45. doi:10.1016/j.jclinane.2004.01.009.

    Article  CAS  PubMed  Google Scholar 

  66. Lloret Linares C, Decleves X, Oppert JM, Basdevant A, Clement K, Bardin C, et al. Pharmacology of morphine in obese patients: clinical implications. Clin Pharmacokinet. 2009;48(10):635–51. doi:10.2165/11317150-000000000-00000.

    Article  PubMed  Google Scholar 

  67. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105 Suppl 1:i16–23. doi:10.1093/bja/aeq312.

    Article  CAS  PubMed  Google Scholar 

  68. Alsio A, Rembeck K, Askarieh G, Christensen PB, Farkkila M, Langeland N, et al. Impact of obesity on the bioavailability of peginterferon-alpha2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS ONE. 2012;7(5), e37521. doi:10.1371/journal.pone.0037521.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  69. Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, et al. Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin Pharmacokinet. 2012;51(8):543–51. doi:10.2165/11632940-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  70. Mornar S, Chan LN, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol. 2012;207(2):110 e1-6. doi:10.1016/j.ajog.2012.05.002.

  71. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1–7. doi:10.1021/js980173a.

    Article  CAS  PubMed  Google Scholar 

  72. Kolka CM, Harrison LN, Lottati M, Chiu JD, Kirkman EL, Bergman RN. Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle. Diabetes. 2010;59(3):619–26. doi:10.2337/db09-0839.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994;37(4):377–80.

    Article  CAS  PubMed  Google Scholar 

  74. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15(11):1484–93.

    Article  CAS  PubMed  Google Scholar 

  75. Dayananda L, Belaval VV, Raina A, Chandana R. Intended intramuscular gluteal injections: are they truly intramuscular? J Postgrad Med. 2014;60(2):175–8. doi:10.4103/0022-3859.132334.

    Article  CAS  PubMed  Google Scholar 

  76. Chantel S, Martin P, Petit P, Massignon D, Dode X, Maire P, et al. Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis. Population Approach Group Europe; 2006.

  77. Livingston EH. The incidence of bariatric surgery has plateaued in the U.S. Am J Surg. 2010;200(3):378–85. doi:10.1016/j.amjsurg.2009.11.007.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46(1):130–6. doi:10.1345/aph.1Q414.

    Article  CAS  PubMed  Google Scholar 

  79. Braghetto I, Davanzo C, Korn O, Csendes A, Valladares H, Herrera E, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg. 2009;19(11):1515–21. doi:10.1007/s11695-009-9954-z.

    Article  PubMed  Google Scholar 

  80. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. doi:10.1111/j.1467-789X.2009.00614.x.

    Article  CAS  PubMed  Google Scholar 

  81. Olson K. Poisoning and drug overdose. 6th ed. New York: McGraw-Hill Education; 2007.

    Google Scholar 

  82. Corcoran GB, Salazar DE. Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat. J Pharmacol Exp Ther. 1989;248(1):17–22.

    CAS  PubMed  Google Scholar 

  83. Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ. Pharmacokinetics of sufentanil in obese patients. Anesth Analg. 1991;73(6):790–3.

    CAS  PubMed  Google Scholar 

  84. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998;89(3):562–73.

    Article  CAS  PubMed  Google Scholar 

  85. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg. 2004;99(4):1090–4. doi:10.1213/01.ANE.0000132781.62934.37.

    Article  CAS  PubMed  Google Scholar 

  86. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99(4):1086–9. doi:10.1213/01.ANE.0000120081.99080.C2.

    Article  PubMed  Google Scholar 

  87. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707–13. doi:10.1200/JCO.2007.11.2938.

    Article  CAS  PubMed  Google Scholar 

  88. Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993;54(4):368–73.

    Article  CAS  PubMed  Google Scholar 

  89. Taivainen T, Tuominen M, Rosenberg PH. Influence of obesity on the spread of spinal analgesia after injection of plain 0.5% bupivacaine at the L3-4 or L4-5 interspace. Br J Anaesth. 1990;64(5):542–6.

    Article  CAS  PubMed  Google Scholar 

  90. Hogan QH, Prost R, Kulier A, Taylor ML, Liu S, Mark L. Magnetic resonance imaging of cerebrospinal fluid volume and the influence of body habitus and abdominal pressure. Anesthesiology. 1996;84(6):1341–9.

    Article  CAS  PubMed  Google Scholar 

  91. Ellero S, Chakhtoura G, Barreau C, Langouet S, Benelli C, Penicaud L, et al. Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010;38(4):679–86. doi:10.1124/dmd.109.029249.

    Article  CAS  PubMed  Google Scholar 

  92. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304. doi:10.2165/11599410-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  93. Snawder JE, Roe AL, Benson RW, Roberts DW. Loss of CYP2E1 and CYP1A2 activity as a function of acetaminophen dose: relation to toxicity. Biochem Biophys Res Commun. 1994;203(1):532–9. doi:10.1006/bbrc.1994.2215.

    Article  CAS  PubMed  Google Scholar 

  94. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med. 1990;113(10):799–800.

    Article  CAS  PubMed  Google Scholar 

  95. Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum. 1985;28(10):1117–21.

    Article  CAS  PubMed  Google Scholar 

  96. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783–90.

    Article  CAS  PubMed  Google Scholar 

  97. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med. 1983;101(6):873–80.

    CAS  PubMed  Google Scholar 

  98. Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology. 1982;57(1):48–9.

    Article  CAS  PubMed  Google Scholar 

  99. Tanaka E, Yamazaki K, Misawa S. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects. J Clin Pharm Ther. 2000;25(5):325–32.

    Article  CAS  PubMed  Google Scholar 

  100. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62(6):423–9. doi:10.1007/s00228-006-0111-5.

    Article  CAS  PubMed  Google Scholar 

  101. Salazar DE, Schentag JJ, Corcoran GB. Obesity as a risk factor in drug-induced organ injury. V. Toxicokinetics of gentamicin in the obese overfed rat. Drug Metab Dispos. 1992;20(3):402–6.

    CAS  PubMed  Google Scholar 

  102. Jesudason DR, Clifton P. Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician. Int J Obes (Lond). 2012;36:1421–7. doi:10.1038/ijo.2011.242.

    Article  CAS  Google Scholar 

  103. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13. doi:10.1056/NEJMoa020245.

    Article  PubMed  Google Scholar 

  104. Abrass CK. Overview: Obesity: what does it have to do with kidney disease? J Am Soc Nephrol. 2004;15(11):2768–72. doi:10.1097/01.ASN.0000141963.04540.3E.

    Article  PubMed  Google Scholar 

  105. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: paradox or reverse epidemiology? Eur Heart J. 2005;26(1):5–7. doi:10.1093/eurheartj/ehi055.

    Article  PubMed  Google Scholar 

  106. Praga M. Obesity—a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157–9.

    Article  PubMed  Google Scholar 

  107. Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013;33:23–33. doi:10.1016/j.semnephrol.2012.12.003.

    Article  PubMed  Google Scholar 

  108. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit. 1998;20:261–5.

    Article  CAS  PubMed  Google Scholar 

  109. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053–60.

    Article  CAS  PubMed  Google Scholar 

  110. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  PubMed  Google Scholar 

  111. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604–12. doi:10.1002/j.1875-9114.2012.01098.x.

    Article  CAS  PubMed  Google Scholar 

  112. Cho S-J, Yoon I-S, Kim D-D. Obesity-related physiological changes and their pharmacokinetic consequences. J Pharm Investig. 2013;43(3):161–9. doi:10.1007/s40005-013-0073-4.

    Article  CAS  Google Scholar 

  113. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–30. doi:10.2165/11598930-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  114. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54:621–5.

    Article  CAS  PubMed  Google Scholar 

  115. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45:48–56. doi:10.1177/0091270004269562.

    Article  CAS  PubMed  Google Scholar 

  116. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51:2741–7. doi:10.1128/AAC.00059-07.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  117. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000;56:293–7.

    Article  CAS  PubMed  Google Scholar 

  118. Barras MA, Duffull SB, Atherton JJ, Green B. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol. 2009;68:700–11. doi:10.1111/j.1365-2125.2009.03518.x.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  119. Willett KC, Alsharhan M, Durand C, Cooper MR. Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. Ann Pharmacother. 2013;47:1717–20. doi:10.1177/1060028013507902.

    Article  CAS  PubMed  Google Scholar 

  120. Bauer LA, Wareing-Tran C, Edwards WA, Raisys V, Ferreri L, Jack R, et al. Cimetidine clearance in the obese. Clin Pharmacol Ther. 1985;37:425–30.

    Article  CAS  PubMed  Google Scholar 

  121. Abernethy DR, Greenblatt DJ, Matlis R, Gugler R. Cimetidine disposition in obesity. Am J Gastroenterol. 1984;79:91–4.

    CAS  PubMed  Google Scholar 

  122. Chyka PA, Seger D, Krenzelok EP, Vale JA, AACT, EAPCCT. Position paper: single-dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61–87.

    Article  CAS  Google Scholar 

  123. McNamara RM, Aaron CK, Gemborys M, Davidheiser S. Efficacy of charcoal cathartic versus ipecac in reducing serum acetaminophen in a simulated overdose. Ann Emerg Med. 1989;18(9):934–8.

    Article  CAS  PubMed  Google Scholar 

  124. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1999;37(6):731–51.

  125. Krag E, Hojgaard L. Bile acid metabolism after intestinal bypass operations. Int J Obes. 1981;5(5):519–25.

    CAS  PubMed  Google Scholar 

  126. Dunning K, Plymyer MR. Charcoal peritonitis causing chronic pelvic pain: a unique complication following bariatric surgery. Obes Surg. 2006;16(9):1238–42. doi:10.1381/096089206778392121.

    Article  PubMed  Google Scholar 

  127. Van Dinter Jr TG, John L, Guileyardo JM, John SF. Intestinal perforation caused by insertion of a nasogastric tube late after gastric bypass. Proc (Baylor Univ Med Cent). 2013;26(1):11–5.

    Google Scholar 

  128. Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J. 2002;19(6):594–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  129. Prizont R. Medical officer review: acetadote. FDA Center for Drug Evaluation and Research: Office of Drug Evaluation. 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote_Medr.pdf. Accessed 16 May 2015.

  130. Duncan R, Cantlay G, Paterson B. New recommendation for N-acetylcystiene dosing may reduce incidence of adverse effects. Emerg Med J. 2006;23(7):584. doi:10.1136/emj.2005.031104.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  131. Intralipid [package insert]. Deerfield: Baxter Healthare Corporation; 2007.

  132. Methylene blue [package insert]. Lake Forest: Akorn, Inc.; 2008.

  133. El-Solh A, Sikka P, Bozkanat E, Jaafar W, Davies J. Morbid obesity in the medical ICU. Chest. 2001;120(6):1989–97.

    Article  CAS  PubMed  Google Scholar 

  134. Akinnusi ME, Pineda LA, El Solh AA. Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med. 2008;36(1):151–8. doi:10.1097/01.CCM.0000297885.60037.6E.

    Article  PubMed  Google Scholar 

  135. Bercault N, Boulain T, Kuteifan K, Wolf M, Runge I, Fleury JC. Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study. Crit Care Med. 2004;32(4):998–1003.

    Article  PubMed  Google Scholar 

  136. Tremblay A, Bandi V. Impact of body mass index on outcomes following critical care. Chest. 2003;123(4):1202–7.

    Article  PubMed  Google Scholar 

Download references

Funding

The authors have no funding to report in relation to this study.

Conflict of Interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. University of Colorado, Anschutz Medical Campus, 12401 East 17th Avenue, Rm 759, Aurora, CO, 80045, USA

    Matthew Zuckerman

  2. Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    Howard A Greller

  3. Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    Howard A Greller

  4. Division of Medical Toxicology, Department of Emergency Medicine, UMass Memorial Medical Center, Worcester, USA

    Kavita M Babu

Authors
  1. Matthew Zuckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard A Greller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kavita M Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Zuckerman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zuckerman, M., Greller, H.A. & Babu, K.M. A Review of the Toxicologic Implications of Obesity. J. Med. Toxicol. 11, 342–354 (2015). https://doi.org/10.1007/s13181-015-0488-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-015-0488-6

Keywords

Search

Navigation